Recital 17, Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 31 Mar 2004cited 3×

The Community should have the means to carry out a scientific assessment of the medicinal products presented in accordance with the decentralised Community authorisation procedures. Moreover, with a view to ensuring the effective harmonisation of administrative decisions taken by Member States with regard to medicinal products presented in accordance with decentralised authorisation procedures, it is necessary to endow the Community with the means to resolve disagreements between Member States concerning the quality, safety and efficacy of medicinal products.

  • Judgment of the General Court (Seventh Chamber, Extended Composition) of 5 May 2021. Pharmaceutical Works Polpharma S.A. v European MedicineDecision

    Lastly, it should be noted that, according to recital 12 of Directive 2001/83, in the event of a disagreement between Member States about the quality, the safety or the efficacy of a medicinal product, a scientific evaluation of the matter …

    5 May 2021 · 62018TJ0611

  • Opinion of Advocate General Medina delivered on 6 October 2022. European Commission and Others v Pharmaceutical Works Polpharma S.A.Decision

    It is important to understand, in the first place, that, in order to avoid ultra vires conduct, any institution or agency of the European Union must derive its competence from a legal act and state a legal basis for the decision to be …

    6 Oct 2022 · 62021CC0438

  • Judgment of the Court (Fourth Chamber) of 16 March 2023. European Commission and Others v Pharmaceutical Works Polpharma S.A.Decision

    Recitals 17 and 19 of Regulation No 726/2004 state: [The European Union] should have the means to carry out a scientific evaluation of the medicinal products presented in accordance with the decentralised … authorisation procedures. …

    16 Mar 2023 · 62021CJ0438